Table 8 Summary of significant associations between circRNA and AML survival
From: The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia
CircRNAs | Roles | Level | AML patients | Sample source | Analytical methods | Survival | References |
|---|---|---|---|---|---|---|---|
Hsa_circ_0001990 | Oncogenic | ↑ in AML | 70 | BM | Kaplan–Meier | OS, P = 0.021 | [73] |
Circ-ANXA2 (Hsa_circ_0035559) | Oncogenic | ↑ in AML | 130 | BM | Kaplan–Meier | OS, P = 0.001; EFS, P = 0.013 | [74] |
CircTASP1 (Hsa_circ_406083; Hsa_circ_0007340) | Oncogenic | ↑ in AML | 60 | PB | Kaplan–Meier | OS, P = 0.0002 | [75] |
Circ-PTK2 (Hsa_circ_104700; Hsa_circ_0005273) | Oncogenic | ↑ in AML | 40 | BM | Kaplan–Meier | OS, P = 0.0001 | [121] |
Hsa_circ_0044907 | Oncogenic | ↑ in AML | 45 | BM | Kaplan–Meier | OS, P < 0.05 | [129] |
Circ_0012152 | Oncogenic | ↑ in AML | 60 | BM | Kaplan–Meier | OS, P = 0.003 | [134] |
CircPLXNB2 (Hsa_circ_0001257) | Oncogenic | ↑ in AML | 40 | BM | Kaplan–Meier | OS, P = 0.0364; LFS, 0.0393 | [138] |
Hsa_circ_0003602 (CircSMARCC1) | Oncogenic | ↑ in AML | 50 | BM | Kaplan–Meier | OS, P = 0.0315 | [144] |
Circ-PVT1 | Oncogenic | ↑ in AML | 23 | BM | Kaplan–Meier | OS, P = 0027; RFS, P = 0.047 | [146] |
|  |  |  | 68 | BM | Kaplan–Meier | OS, P = 0.026; EFS, P = 0.017 | [174] |
|  |  |  | 68 | BM | Multivariate Cox’s regression analysis | OS, P = 0.029; EFS, P = 0.043 | [174] |
Circ_001264 | Oncogenic | ↑ in AML; ↑ in AML cell-derived exosomes | 50 | PB | Kaplan–Meier | OS, P < 0.01 | [150] |
Circ_0040823 | Antitumour | ↓ in AML; ↓ in AML serum | 68 | PB | Kaplan–Meier | OS, P = 0.029; DFS, P = 0.020 | [154] |
CircKLHL8 | Antitumour | NR | 111 | BM, PB | Kaplan–Meier | OS, P < 0.001; DFS, P < 0.001; EFS, P < 0.001 | [172] |
CircSMC1 A | Antitumour | NR | 111 | BM, PB | Kaplan–Meier | OS, P = 0.004; DFS, P = 0.002; EFS, P = 0.02 | [172] |
CircFCHO2 | Antitumour | NR | 111 | BM, PB | Kaplan–Meier | OS, P = 0.003; DFS, P = 0.02; EFS, P = 0.01 | [172] |
CircCFLAR | Antitumour | NR | 111 | BM, PB | Kaplan–Meier | OS, P = 0.003; DFS, P = 0.03; EFS, P = 0.03 | [172] |
Hsa_circ_0079480 | Oncogenic | ↑ in AML serum | 236 | PB | Kaplan–Meier | OS, P < 0.05; RFS, P < 0.05 | [175] |
|  |  |  | 236 | PB | Multivariate Cox proportional hazards regression analysis | OS, P = 0.009; RFS, P = 0.002 | [175] |
Circ_0059706 | Antitumour | ↓ in AML | 57 | BM | Kaplan–Meier | OS, P = 0.047 | [177] |